UHPLC-MS phytochemical profiling, biological propensities andin-silicostudies ofAlhagi maurorumroots: a medicinal herb with multifunctional properties / Hammad Saleem, Muhammad Sarfraz, Kashif Maqbool Khan, Muhammad Aijaz Anwar, Gokhan Zengin, Irshad Ahmad, Shafi-Ullah Khan, Mohamad Fawzi Mahomoodally, Nafees Ahemad
Abstract The biological, chemical, and in silico properties of methanol and dichloromethane (DCM) extracts of Alhagi maurorum roots with respect to the antioxidant, enzyme inhibition, and phytochemical composition were evaluated. Total bioactive contents were determined spectrophotometrically, and the individual secondary metabolites composition was assessed via ultra-high-performance liquid chromatography mass spectrometry (UHPLC-MS) analysis. Antioxidant capacities were evaluated using a panoply of assays (2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2’-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) free radical scavenging, ferric reducing antioxidant power (FRAP), cupric reducing antioxidant power (CUPRAC), phosphomolybdenum total antioxidant capacity (TAC), and metal chelating activity (MCA)). The enzyme inhibition potential was studied against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), α-amylase, α-glucosidase, tyrosinase, urease and lipoxygenase (LOX) enzymes. The methanol extract was found to contain higher total phenolic (105.91 mg GAE/g extract) and flavonoid (2.27 mg RE/g extract) contents which can be correlated to its more substantial antioxidant potential as well as AChE, BChE, tyrosinase and α-glucosidase inhibition. However, the DCM extract was the most effective against α-amylase (1.86 mmol ACAE/g extract) enzyme inhibition. The UHPLC-MS analysis of methanol extract identified the tentative presence of a total of 18 secondary metabolites, including flavonoids, saponins, phenolic and terpenoid derivatives. Three compounds named emmotin A, luteolin 5,3’-dimethyl ether, and preferrugone were further investigated for their in silico molecular docking studies against the tested enzymes. The selected compounds were found to have higher binding interaction with AChE followed by BChE, α-glucosidase, α-amylase, and tyrosinase. The results of the present study have demonstrated A. mauroram to be considered as a lead source of natural antioxidant and enzyme inhibitor compounds.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
---|---|
Enthalten in: |
Drug development and industrial pharmacy - 46(2020), 5, Seite 861-868 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Saleem, Hammad [VerfasserIn] |
---|
Links: |
FID Access [lizenzpflichtig] |
---|
Themen: |
Alhagi maurorum |
---|
Umfang: |
1 Online-Ressource (8 p) |
---|
doi: |
10.1080/03639045.2020.1762199 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
KFL011187891 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | KFL011187891 | ||
003 | DE-627 | ||
005 | 20230720210153.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230714s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/03639045.2020.1762199 |2 doi | |
035 | |a (DE-627)KFL011187891 | ||
035 | |a (KFL)prod_LgpH_10.1080/03639045.2020.1762199 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
084 | |a PHARM |q DE-84 |2 fid | ||
100 | 1 | |a Saleem, Hammad |e verfasserin |4 aut | |
245 | 1 | 0 | |a UHPLC-MS phytochemical profiling, biological propensities andin-silicostudies ofAlhagi maurorumroots: a medicinal herb with multifunctional properties |c Hammad Saleem, Muhammad Sarfraz, Kashif Maqbool Khan, Muhammad Aijaz Anwar, Gokhan Zengin, Irshad Ahmad, Shafi-Ullah Khan, Mohamad Fawzi Mahomoodally, Nafees Ahemad |
264 | 1 | |c 2020 | |
300 | |a 1 Online-Ressource (8 p) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract The biological, chemical, and in silico properties of methanol and dichloromethane (DCM) extracts of Alhagi maurorum roots with respect to the antioxidant, enzyme inhibition, and phytochemical composition were evaluated. Total bioactive contents were determined spectrophotometrically, and the individual secondary metabolites composition was assessed via ultra-high-performance liquid chromatography mass spectrometry (UHPLC-MS) analysis. Antioxidant capacities were evaluated using a panoply of assays (2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2’-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) free radical scavenging, ferric reducing antioxidant power (FRAP), cupric reducing antioxidant power (CUPRAC), phosphomolybdenum total antioxidant capacity (TAC), and metal chelating activity (MCA)). The enzyme inhibition potential was studied against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), α-amylase, α-glucosidase, tyrosinase, urease and lipoxygenase (LOX) enzymes. The methanol extract was found to contain higher total phenolic (105.91 mg GAE/g extract) and flavonoid (2.27 mg RE/g extract) contents which can be correlated to its more substantial antioxidant potential as well as AChE, BChE, tyrosinase and α-glucosidase inhibition. However, the DCM extract was the most effective against α-amylase (1.86 mmol ACAE/g extract) enzyme inhibition. The UHPLC-MS analysis of methanol extract identified the tentative presence of a total of 18 secondary metabolites, including flavonoids, saponins, phenolic and terpenoid derivatives. Three compounds named emmotin A, luteolin 5,3’-dimethyl ether, and preferrugone were further investigated for their in silico molecular docking studies against the tested enzymes. The selected compounds were found to have higher binding interaction with AChE followed by BChE, α-glucosidase, α-amylase, and tyrosinase. The results of the present study have demonstrated A. mauroram to be considered as a lead source of natural antioxidant and enzyme inhibitor compounds | ||
653 | |a Alhagi maurorum | ||
653 | |a phytochemicals | ||
653 | |a antioxidants | ||
653 | |a enzyme inhibition | ||
653 | |a UHPLC-MS | ||
700 | 1 | |a Sarfraz, Muhammad |e verfasserin |4 aut | |
700 | 1 | |a Khan, Kashif Maqbool |e verfasserin |4 aut | |
700 | 1 | |a Anwar, Muhammad Aijaz |e verfasserin |4 aut | |
700 | 1 | |a Zengin, Gokhan |e verfasserin |4 aut | |
700 | 1 | |a Ahmad, Irshad |e verfasserin |4 aut | |
700 | 1 | |a Khan, Shafi-Ullah |e verfasserin |4 aut | |
700 | 1 | |a Mahomoodally, Mohamad Fawzi |e verfasserin |4 aut | |
700 | 1 | |a Ahemad, Nafees |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drug development and industrial pharmacy |d Abingdon : Taylor & Francis Group, 1977 |g 46(2020), 5, Seite 861-868 |h Online-Ressource |w (DE-627)KFL000005975 |w (DE-600)2008903-X |w (DE-576)116897511 |x 1520-5762 |7 nnns |
773 | 1 | 8 | |g volume:46 |g year:2020 |g number:5 |g pages:861-868 |
856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/03639045.2020.1762199 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
912 | |a ZDB-1-TFE | ||
912 | |a GBV_KFL | ||
912 | |a FID-PHARM | ||
935 | |i IMPORT_0628_prod_LgpH_02 | ||
951 | |a AR | ||
952 | |d 46 |j 2020 |e 5 |h 861-868 |